Several studies discovered that APOE4 carriers, whether healthy or diagnosed with AD, demonstrate an accelerated rate of cognitive impairment after follow-up when compared to non-carriers (Cosentino et al., 2008; Rawle et al., 2018; Emrani et al., 2020; Gharbi-Meliani et al., 2021). Here, APOE is linked to Alzheimer disease.